Abstract

Retinitis pigmentosa (RP) is a heterogeneous group of genetically inherited degenerative disorders characterized by progressive loss of peripheral vision. Tran’s corneal electrical stimulation (TES) has been proposed as a treatment for various ocular conditions, but its mechanism remains uncertain. This systematic review and meta-analysis aimed to assess the safety and efficacy of trans-corneal electrical stimulation (TcES) as a treatment for RP by comprehensively examining the available literature in medical databases. The literature of the related studies was retrieved from five databases including central, midline, scopus, directory of open access journals, and clinicalTrials.gov. All of the selected scholarly databases were extensively searched online for articles that were published between January 2019 and July 2023. TES was found to be safe for RP patients, with positive effects on the visual field area (VFA) and scotopic b-wave amplitude. It significantly attenuated the annual decline in the visual field hence effectively doubling its half-life from 10 to 20 years. No significant side effects were observed during TES. TES offers a promising treatment option for RP, with potential benefits in slowing disease progression and preserving vision. The OkuStim system and TES present an affordable and adaptable approach, with opportunities for patient self-administration. However, further studies with larger sample sizes and longer durations are needed to confirm these findings and optimize treatment parameters.

Key words: Retinitis pigmentosa, transcorneal electrical stimulation, electrical stimulation, treatment efficacy, systemic review.